You are here:Home
»
Biochemicals
»
Biochem-Inhibitors
»
Dasatinib (N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, BMS-354825)
Dasatinib
(N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidin
yl]amino]-5-thiazolecarboxamide, BMS-354825)
Pricing
For pricing information, USA customers sign in. Outside USA? Please contact your distributor for pricing. Specifications
| Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastatic melanoma. | | | Catalog # | D1079 | | Related Substances (HPLC) | Any single impurity: | | 0.5% | | Total Impurities: | | 1.0% | | Solubility | Insoluble in water and slightly soluble in ethanol and methanol | | Method for Determining Identity | Proton NMR Spectroscopic Analysis, HPLC | | Loss on Drying | 0.5% | | Residue on ignition | 0.2% | | Heavy Metals | 0.002% | | CAS Number | 302962-49-8 | | Molecular Formula | C22H26ClN7O2S | | Molecular Weight | 488.1 | | Source | Synthetic | | Purity | ~99% | | Form | Supplied as an off-white to pale yellow powder | | | Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. | | Alternate names | N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide |
External Links
|
